Latest / Community Health Media
T-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar
How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer?
Drs. Jason Mouabbi and Neil Iyengar discuss the evolving role of trastuzumab deruxtecan (T-DXd) plus pertuzumab in first-line metastatic HER2-positive breast cancer and how the DESTINY-Breast09 findings are influencing clinical decision-making.
They examine how this approach compares with the long-standing CLEOPATRA regimen, why depth and duration of response matter, and how clinicians can balance efficacy, tolerability, maintenance strategies, and future treatment sequencing when…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.